Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:56:24.861Z.
Calculation as of: 2026-10-06T15:56:24.861Z.
Quote observation: 2026-10-06T15:55:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$137.92M
PS Ratio
0.92
TTM Avg
1.60
3Y Avg
1.64
5Y Avg
2.33
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Freenome, Inc. (FRNM) | $136.27M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.86M | 3.03 | 4.98 | 4.43 | 4.81 |
| Atrium Therapeutics, Inc. (RNA)vs › | $137.19M | 5.84 | 8.11 | 8.11 | 8.11 |
| Pyxis Oncology, Inc. (PYXS)vs › | $134.80M | 12.21 | 33.16 | 22.27 | 22.27 |
| LifeMD, Inc. (LFMD)vs › | $134.69M | 0.66 | 0.81 | 1.35 | 1.16 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $137.92M | 0.92 | 1.60 | 1.64 | 2.33 |
| Organigram Global Inc. (OGI)vs › | $133.13M | 0.60 | 1.00 | 1.14 | 2.45 |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 2.04 | 7.67 | 3.96 | 3.05 |
| Health Catalyst, Inc. (HCAT)vs › | $131.53M | 0.45 | 0.46 | 1.01 | 2.15 |
| Alpha Cognition Inc (ACOG)vs › | $141.33M | 9.26 | 14.60 | 22.81 | 22.81 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
